BioPharmSignal logoBioPharmSignal

Biotech News

Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026

Cellectar Biosciences (CLRB)Cellectar BiosciencesEarnings

CLRB (CLRB) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is clrb.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

CLRBCellectar Biosciences2026-07-30 12:05 EST

Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026

CLRBCellectar Biosciences2026-07-15 11:30 EST

Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers

IDYAIDEAYA Biosciences2026-08-04 10:00 EST

IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

IMCRImmunocore Holdings plc2026-07-30 11:00 EST

Immunocore to report second quarter 2026 financial results and host call on August 6, 2026

REGNRegeneron Pharmaceuticals2026-06-25 20:05 EST

Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast

SNDXSyndax Pharmaceuticals2026-07-28 11:00 EST

Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026

TEVATeva Pharmaceutical Industries2026-06-18 20:30 EST

Teva to Host Conference Call to Discuss Second Quarter 2026 Financial Results on July 29, 2026 at 8 a.m. ET

BNTXBioNTech2026-07-21 10:45 EST

BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026

ARGXArgenx2026-07-16 05:00 EST

argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026

LYELLyell Immunopharma2026-08-06 20:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026

View all latest news

Cellectar Biosciences

Phospholipid Drug Conjugate Platform Cellectar Biosciences develops cancer therapies using its Phospholipid Drug Conjugate platform, which is designed to deliver radioisotopes selectively to malignant cells while limiting off-target exposure. Iopofosine I 131 Iopofosine I 131 is the company’s lead radioconjugate and has produced clinical...

Recent company news

CLRBCellectar Biosciences2026-07-30 12:05 EST

Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026

CLRBCellectar Biosciences2026-07-15 11:30 EST

Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers

CLRBCellectar Biosciences2026-06-01 12:05 EST

Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting

CLRBCellectar Biosciences2026-05-14 11:15 EST

Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

CLRBCellectar Biosciences2026-05-11 12:05 EST

Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026

Stock data

Close
2.52 USD
Market cap
21.9M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States